Navigation Links
Inspiration Biopharmaceuticals Presents Safety Data on IB1001, a Novel Recombinant Factor IX for the Treatment of Hemophilia at the International Society on Thrombosis and Haemostasis (ISTH) Annual Meeting
Date:7/14/2009

LAGUNA NIGUEL, Calif., July 14 /PRNewswire/ -- Inspiration Biopharmaceuticals today announced the presentation of positive preclinical safety, toxicology and preliminary pharmacokinetic data on its lead product, IB1001, a novel recombinant Factor IX product to treat patients with hemophilia B. The data were highlighted in an oral presentation yesterday at the XXII Congress of the International Society on Thrombosis and Haemostasis (ISTH) in Boston, Mass. IB1001 has completed preclinical testing and is currently being evaluated in a Phase 1/2-3 clinical study.

In the study, the safety, toxicology and pharmacokinetics of IB1001 were evaluated in animal models and compared to commercially available Factor IX products. Results showed that IB1001 has an excellent safety profile in animal models and a similar pharmacokinetic profile when compared to currently available Factor IX products.

"These results and the progress that we have made in advancing our protein manufacturing technology have facilitated the advancement of IB1001 into a Phase 1/2-3 clinical program," said Michael Griffith, Ph.D., President and CEO, Inspiration Biopharmaceuticals. "Our ultimate goal is to increase accessibility to prophylactic treatment and improve the quality of life for people suffering from hemophilia around the world. We expect to move IB1001 into a pivotal trial and look forward to updating you on all developments related to this program."

About IB1001

IB1001 is an intravenous recombinant Factor IX product for the acute and preventative treatment of the bleeding disorder associated with hemophilia B. IB1001 is produced with Inspiration's proprietary recombinant protein manufacturing technology, which significantly increases cell-line productivity.

About Hemophilia

Hemophilia is a lifelong, inherited bleeding disorder cause
'/>"/>

SOURCE Inspiration Biopharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Gyros Raises SEK 80 Million to Accelerate the Commercialization of its Gyrolab(R) Systems for the Cost-Efficient Development of Biopharmaceuticals
2. Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex (Ferric Citrate) for the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients
3. Keryx Biopharmaceuticals Announces Appointment of Ron Bentsur as Chief Executive Officer
4. Keryx Biopharmaceuticals Announces Poster Presentations Highlighting Clinical Activity of KRX-0401 (Perifosine) at the Upcoming Annual Meeting of the American Society of Clinical Oncology
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on First Quarter 2009 Financial Results on Thursday, May 14, 2009 at 8:30am EDT
6. Keryx Biopharmaceuticals, Inc. Announces Michael P. Tarnok as Interim Chairman and Chief Executive Officer
7. Keryx Biopharmaceuticals Presents Encouraging Preclinical Data at Annual Meeting of the American Association of Cancer Research
8. XTL Biopharmaceuticals Ltd. Receives Notification of Delisting Determination by NASDAQ Listing Qualifications Panel
9. The Need for Safe and Affordable Biopharmaceuticals Drives the Development of the European Biosimilars Market, Says Frost & Sullivan
10. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results
11. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2008 Financial Results on Friday, March 13, 2009 at 8:30am EDT

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2009)... , , Vernier,s experience in data analy...orer (TM) program kits and curricula provi...cation ,, BEAVERTON, Ore., Nov. 18 /PRNewswir...r of educational science interfaces, sensors, and ...tional manufacturer and distributor of life scienc...
(Date:11/18/2009)... , , EAST GRINSTEAD, West Sussex, U.K. and...c Systems, a Magellan Biosciences business and pre...lity products for microbiology labs, has expanded ...ch and development facility to meet increasing glo...or susceptibility and identification testing. The ...
(Date:11/18/2009)... , , MISSISSAUGA, ON, Nov. 18 /PRNewswire-F... TSX: YM), a life sciences product development com...lio of promising cancer-related products at variou...om a study evaluating nimotuzumab were presented t...lar Targets and Cancer Therapeutics conference in ...
(Date:11/18/2009)... , , BONITA SPRINGS, Fla., Nov. 18 /PRNe...ect-to-Ethanol® technology, and the technol...te in a joint development project in order to iden...) and oxygen (O2) for Algenol,s unique algae and p...ee the companies join forces to develop cost-effic...
Breaking Biology Technology:Vernier and Bio-Rad to Offer Enhanced Solutions for Biotechnology Education 2TREK Diagnostic Systems Opens New U.K. Facility in East Grinstead to Meet Expanded Customer Demand for Microbiology Products 2TREK Diagnostic Systems Opens New U.K. Facility in East Grinstead to Meet Expanded Customer Demand for Microbiology Products 3TREK Diagnostic Systems Opens New U.K. Facility in East Grinstead to Meet Expanded Customer Demand for Microbiology Products 4YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB RESULTS IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER MODEL PRESENTED AT AACR-NCI-EORTC MEETING 2YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB RESULTS IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER MODEL PRESENTED AT AACR-NCI-EORTC MEETING 3Algenol Biofuels and The Linde Group Agree To Cooperate in CO2 and O2 Management For Biofuel Production From Algae 2Algenol Biofuels and The Linde Group Agree To Cooperate in CO2 and O2 Management For Biofuel Production From Algae 3
..., April 9 /PRNewswire-FirstCall/ - OncoGenex Pharm...ASDAQ: OGXI ), announced today that it has been ...y LifeSciences British Columbia. This annual award...recognize a local organization that has made outst... Columbia,s life sciences industry. This award rec...
... Cell Biosciences, a provider of nanoproteomic an...announced the closing of a $10 million Series C fi...me Trust. Existing investors Domain Associates, L...es, Royal Bank of Canada and The Vertical Group al...y happy to announce this financing in the current ...
... 9 Cepheid (Nasdaq: CPHD ) today announced that...irst quarter ended March 31, 2009, on Thursday, Ap...The company will host a management presentation at...to discuss the results. To access the live webcas....com/investors at least 15 minutes before the sc...
Other Biology Technology:OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia 2OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia 3Cell Biosciences Closes $10 Million Series C Financing 2Cepheid Schedules Fiscal 2009 First Quarter Financial Results Announcement and Webcast 2
(Date:11/20/2009)...vember 19, 2009 The estimated 4.6 million America...of developing respiratory symptoms due to poor air...ire study undertaken earlier this year by investig...erinary Medicine. , The studywhich polled more t... percent of individuals working in barns complaine...
(Date:11/20/2009)...le in German . , In the current online issu...Stefanie Eyerich and Dr. Kilian Eyerich together w...and Istituto Dermopatico dell,Immacolata in Rome, ...nts a milestone on the way to developing new treat...s psoriasis and allergic reactions and potentially...
(Date:11/20/2009)...w study, researchers report that a class of heart ...l, or harmful, effect on the heart, depending on t...ars in the journal Circulation Research , found t...beta-receptors on the heart muscle offer the most ...et only the beta-receptors can actually undermine ...
Breaking Biology News(10 mins):Barn personnel experience higher-than-average rates of respiratory symptoms 2Discovery of new type of immune cells regulating inflammation in chronic diseases 2Carvedilol shown to have unique characteristics among beta blockers 2Scientists identify gene vital to early embryonic cells forming a normal heart and skull 12703 1Scientists identify gene vital to early embryonic cells forming a normal heart and skull 12703 2Norway Japan prop up whaling industry with taxpayer money 8913 1Norway Japan prop up whaling industry with taxpayer money 8913 2Burner Balm Joins Forces With Call to the Wall 49440 1
...sons are the Clark Kents of a genome. Apparently m...ursts of activity, these free-floating bits of gen...king into the genetic maps of plants and animals, ...ars, researchers thought that most of this DNA was...ings, however, are peeling back the odd and baffli...
... i.e. substances which can be stimulated to emit ...research and medical diagnosis. Fluorescence can b...expression of genes, to locate proteins in cells a...udy the location and migration of cells. Of partic... imaging with novel techniques that allow tomograp...
...ldstein checks his lobster traps in New Hampshire,... crustaceans to sell. Instead, the University of N...ters with transmitters and tracking their migratio... along the New Hampshire coastline and into Great ...funded by N.H. Sea Grant, will provide more accura...
Other Biology News:New research shows how gene function drives natural selection in important class of genetic elements 2New research shows how gene function drives natural selection in important class of genetic elements 3Novel technique for fluorescence tomography of tumors in living animals 2UNH researchers track lobster migrations to improve population estimates 2UNH researchers track lobster migrations to improve population estimates 3
...us venom Description: Phosphodiesterase I (venom e...d structure and sequence (1) . It hydrolyzes 5'-mo...onucleotides and deoxyribo-oligonucleotides (2) . ...ns at the pyrophosphate linkages to yield phosphor...
Spacer for Miniature FRENCH Pressure Cell from Thermo Scientific
...criptase is a recombinant Moloney murine leukemia ... Reverse Transcriptase is similar to MuLV reverse .... MuLV reverse transcriptase is a recombinant RNA-... RNA as a template in the presence of a primer to ...
...to Prostaglandin F2α (8-iso-13,14-dihydro-1...stane, 8-isoprostane (8-iso PGF2α), in rabb...G-like product of non-specific lipid peroxidation....-isoprostane is converted primarily to metabolites...
Biology Products: